Luis I. Ruffolo

Also affiliated with University of Rochester Medicine, Albany Research Institute, Buffalo BioLabs, University of Rochester, Syracuse University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.”.

A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps631

N/A

0DataRank · unranked

10 citations

Nicholas A. Ullman, Brian A. Belt, Luis I. Ruffolo, Paul R. Burchard, Aram F. Hezel +7 more

Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4195

N/A

0DataRank · unranked

0 citations

Terrence L. Fisher, Elizabeth E. Evans, Crystal Mallow, Megan Boise, Amber Foster +7 more